00:00Actually, yes, it is possible that it is not only problem of India, it has been found that there are
00:12many strains of many bacterias which are now antibacterial resistant.
00:17In fact, some of the common bacterias which were everywhere like E. coli bacterias like this, these are now resistant
00:26to some of the common antibacterial like amoxilins or azithromycins.
00:30So it is a big problem now, but people are working on it throughout the world including India and the
00:38government has also announced several programs.
00:42Actually, there is a national action plan for antimicrobial resistance.
00:47The government has, I think you can find in the website, there are more than 200 pages where they have
00:54meticulously and elaborately put all the plan including,
01:00I think there are seven or eight ministries that are involved.
01:03So it is possible, it is actually real danger, not only for the, like, it is also a danger for
01:10public health and public health and community health.
01:14So it is a big problem.
01:15This cleft cerebral pneumonia, the bacteria, it is actually really dangerous.
01:21In a sense, specially for pneumonia, urinary tract infections and some blood trend infections and also wound infections.
01:30There are some strains that are found, especially there is one strain and this is actually called New Delhi.
01:37New Delhi metallic bacteria, it is called NDM.
01:42So it is actually found in Indian hospitals.
01:47Especially these bacteria are more dangerous, some of the strains are most dangerous.
01:51If this bacteria is found in hospitals.
01:54If this bacteria is found in hospitals, it is mostly found in hospitals.
02:03So it is very dangerous.
02:13Because in hospitals, you have a newborn guy, then there are critical ill patients, there are cancer patients.
02:19So it is very dangerous.
02:21And then there are some, let's say, those hospitals which are not very clean.
02:26They do not maintain certain level of hygiene or etc.
02:31Then some contaminated apparatus, so it is problematic.
02:38So it is problematic.
02:38Now I have seen that the cleft cerebral pneumonia is in fact some of the very expensive antibiotics.
02:47Meropenem, Carbopenem-based, Bitalactamase-based.
02:50There are some resistance strains.
02:53So these are really dangerous.
02:55Primarily, we are actually a computational group.
02:58But in this project, there are two techniques used in this project.
03:03One is normal molecular dynamics, which is physics-based simulation.
03:07The second is AI-based.
03:08Artificial intelligence with machine learning techniques.
03:11And the third is validation, which is a company.
03:13Mangalore-based company.
03:15So primarily, what do we do?
03:17The bacteria, the protein, the bacteria.
03:20And there are different mechanisms by which the drug is basically resistant.
03:27The first is the target.
03:30The target is slightly modified.
03:32The bacteria, the protein, the bacteria.
03:34The second is the bacteria in a sale called efflux pump.
03:39The antibiotic is coming out.
03:42So the bacteria in the concentration is working.
03:47So the target of this project is called efflux pump.
03:52The efflux pump is called efflux pump.
03:55We have been doing this for a long time.
03:57So detailed study can now with respect to that particular antibiotics.
04:01And then we'll modify certain antibiotics.
04:03And using the AI-based technique, we'll search for a huge number of molecules.
04:09For example, we are planning to have almost a million molecules to find out which are effective,
04:14at least to some extent effective.
04:16And then we'll do some experimental validations.
04:19But yes, so it will have physics-based simulations, then we have AI, and then there are some experimental part
04:26of it.
04:33It is not a job of a single group or a single company.
04:39So if you can see it in history, it takes around 6-7 years or even sometimes it has taken
04:4610 years to develop a new antibiotic.
04:48Especially the class of antibiotics.
04:56But we will give you some lead molecules.
04:59But again, it has to go through extensive experimental technique, including animal models and clinical models.
05:06So yes, in a sense, we will contribute towards the goal.
05:10But we cannot claim that our molecules will be a new antibiotic.
05:13But that is, nobody can claim it, unless it is going through the extensive experimental validations, including animal models, clinical
05:23trials, etc.
05:24.